Radiation oncology journal最新文献

Analysis of radiotherapy in patients with intermediate- and high-risk meningiomas. 中高危脑膜瘤放疗疗效分析。

Radiation oncology journal Pub Date : 2025-09-01 Epub Date: 2025-09-09 DOI: 10.3857/roj.2025.00248

Jisang Kim, Jin-Ho Song, So Jung Lee

{"title":"Analysis of radiotherapy in patients with intermediate- and high-risk meningiomas.","authors":"Jisang Kim, Jin-Ho Song, So Jung Lee","doi":"10.3857/roj.2025.00248","DOIUrl":"10.3857/roj.2025.00248","url":null,"abstract":"Purpose: This study aimed to investigate treatment outcomes in patients with intermediate- and high-risk meningioma who underwent radiotherapy (RT) and identify prognostic factors for progression-free survival (PFS). In addition, failure patterns after RT were analyzed.Materials and methods: We retrospectively reviewed 61 patients with intermediate- and high-risk meningiomas, categorized according to the NRG Oncology/Radiation Therapy Oncology Group 0539 trial, who underwent surgery followed by adjuvant or salvage RT.Results: We included 12 and 49 patients with intermediate- and high-risk meningiomas, respectively. A total of 26 cases of tumor progression and 17 deaths after RT were identified. The 5-year PFS and overall survival of the entire cohort were 55.8% and 74.2%; intermediate-risk group, 80.2% and 100%; high-risk group, 48.7% and 67.1%, respectively. The World Health Organization (WHO) grade 3 (hazard ratio [HR], 16.7; 95% confidence interval [CI], 3.0 to 92.3; p = 0.001) and recurrent tumor (HR, 41.2; 95% CI, 3.6 to 473.6; p = 0.003) were identified as adverse prognostic factors for PFS in high-risk patients. Among the 15 patients who had recurrence after conventional fractionated radiotherapy (CFRT), 13 experienced local failure (LF) and two experienced distant failure.Conclusion: RT with adjuvant or salvage intent showed favorable treatment outcomes in patients with intermediate- to high-risk meningioma. WHO grade 3 histology and recurrent tumors were identified as adverse prognostic factors for PFS in high-risk patients. LF was the dominant failure pattern after CFRT, accounting for 86.7% of all recurrences. These findings underscore the need for further studies on dose-escalated RT to enhance local control in patients with these adverse features.","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"43 3","pages":"135-143"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12510748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implications of interfractional bladder volume variations in proton beam therapy for rectal cancer. 直肠癌质子束治疗中膀胱容积变化的意义。

Radiation oncology journal Pub Date : 2025-09-01 Epub Date: 2025-06-09 DOI: 10.3857/roj.2024.00654

Johanna Färlin, Bruno Sorcini, Karin Söderkvist, Alexander Valdman

{"title":"Implications of interfractional bladder volume variations in proton beam therapy for rectal cancer.","authors":"Johanna Färlin, Bruno Sorcini, Karin Söderkvist, Alexander Valdman","doi":"10.3857/roj.2024.00654","DOIUrl":"10.3857/roj.2024.00654","url":null,"abstract":"Purpose: This study evaluated interfractional bladder volume variations and the resulting dosimetric changes during short-course radiotherapy (SCRT) 5X5Gy (RBE) in patients with locally advanced rectal cancer.Materials and methods: Twenty patients received either protons or photons with daily cone-beam CT (CBCT). All patients received the same drinking instructions prior to the planning CT and each fraction. For each patient, VMAT and PBT plans were generated. The bladder was delineated on each CBCT which were registered to the planning CT in the treatment planning system. The baseline Bowel bag structure was adjusted accordingly for each bladder volume. Volumetric and dosimetric data for the bladder and Bowel bag were then analyzed.Results: Baseline bladder volumes were on average 71 cm3 larger than the average volume during treatment (95% confidence interval, 15 to 126). No significant difference was detected during treatment. Mean bladder doses decreased significantly from baseline to during treatment for both VMAT and PBT treatment plans (p = 0.021 and p = 0.002, paired two-sided t-test). Compared to baseline, the dose to the bowel bag adjusted for daily bladder volume increased by 3.8% for VMAT (t = -2.56, p = 0.019, two-tailed) and 18.7% for PBT (t= -2.415, p = 0.026, two-tailed).Conclusion: We report consistently smaller bladder volumes during SCRT compared to baseline. This resulted in lower-than-expected mean bladder doses during the treatment course and consequently an increase in dose to Bowel bag. Variations in bladder volume resulted in larger changes in delivered dose to bladder and bowel bag in PBT compared to VMAT.","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"43 3","pages":"120-127"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12510746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is there a role of radiotherapy for steroid-resistant thyroid eye disease? 放射治疗对类固醇抵抗性甲状腺眼病有作用吗？

Radiation oncology journal Pub Date : 2025-09-01 Epub Date: 2025-09-25 DOI: 10.3857/roj.2025.00556

Jae Myoung Noh

引用次数: 0

Optimizing palliative radiotherapy for breast cancer with skin involvement: technical and methodologic considerations. 优化姑息性放疗对皮肤受累乳腺癌：技术和方法学的考虑。

Radiation oncology journal Pub Date : 2025-09-01 Epub Date: 2025-08-18 DOI: 10.3857/roj.2025.00311

Gonca Altınışık İnan, İpek Pınar Aral, Çağkan Ergiden, Fatma Betül Ayrak, Volkan Çevik

引用次数: 0

Prognostic factors and risk stratification for survival in oligometastatic colorectal cancer treated with stereotactic body radiotherapy. 立体定向放射治疗少转移性结直肠癌的预后因素和生存风险分层。

Radiation oncology journal Pub Date : 2025-09-01 Epub Date: 2025-06-30 DOI: 10.3857/roj.2025.00066

Hyunji Kim, Bong Kyung Bae, Gyu-Seog Choi, Jong Gwang Kim, Jun Seok Park, Soo Yeun Park, Hye Jin Kim, Jin Ho Baek, Byung Woog Kang, An Na Seo, Min Kyu Kang

{"title":"Prognostic factors and risk stratification for survival in oligometastatic colorectal cancer treated with stereotactic body radiotherapy.","authors":"Hyunji Kim, Bong Kyung Bae, Gyu-Seog Choi, Jong Gwang Kim, Jun Seok Park, Soo Yeun Park, Hye Jin Kim, Jin Ho Baek, Byung Woog Kang, An Na Seo, Min Kyu Kang","doi":"10.3857/roj.2025.00066","DOIUrl":"10.3857/roj.2025.00066","url":null,"abstract":"Purpose: This study aimed to evaluate treatment outcomes with associated prognostic factors, and to guide treatment strategies in colorectal cancer patients with oligometastatic disease (OMD) treated with stereotactic body radiotherapy (SBRT).Materials and methods: This retrospective study included 74 colorectal cancer patients who received SBRT for 113 lesions (88 lung, 19 liver, and 6 lymph node). Each OMD was considered a separate case for patients repeatedly diagnosed with OMD. The log-rank test and Cox proportional hazards model were used to assess prognostic factors for progression-free survival (PFS).Results: A total of 84 cases were analyzed. The median follow-up period was 32.2 months (range, 8.2 to 89.3 months). The 2-year PFS, widespread failure-free survival (WSFFS), and overall survival (OS) rates were 35.1%, 67.4%, and 80.8%, respectively. In the multivariable analysis, oligometastatic status (repeat/induced vs. de novo; hazard ratio [HR], 2.66; 95% confidence interval [CI], 1.40 to 5.04; p = 0.003) and planning target volume (PTV) volume (17.6 vs. <17.6 cm3; HR, 1.99; 95% CI, 1.09 to 3.62; p = 0.025) were significant prognostic factors for PFS. Cases with two risk factors for PFS demonstrated significantly worse OS and WSFFS (p < 0.05), whereas those with one risk factor did not show a significant difference compared to cases with no risk factors.Conclusion: SBRT for oligometastatic colorectal cancer showed favorable clinical outcomes. Oligometastatic status and PTV volume were significantly associated with PFS. Risk stratification based on the number of poor prognostic factors of PFS may help guide treatment strategies for colorectal cancer patients with OMD.","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"43 3","pages":"128-134"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12510751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Technique and outcomes of high-dose-rate interstitial brachytherapy for lip and buccal mucosa cancer: emphasis on cosmetic results. 高剂量间质近距离放射治疗唇、颊粘膜癌的技术和效果：重点是美容效果。

Radiation oncology journal Pub Date : 2025-09-01 Epub Date: 2025-06-10 DOI: 10.3857/roj.2024.00682

Subhas Pandit, Simit Sapkota, Jeebana Bhandari, Abish Adhikari, Deepak Yadav, Rijendra Yogal, Rajan Prajapati, Sangam Rayamajhi, Sunil Shrestha, Anjani Kumar Jha

{"title":"Technique and outcomes of high-dose-rate interstitial brachytherapy for lip and buccal mucosa cancer: emphasis on cosmetic results.","authors":"Subhas Pandit, Simit Sapkota, Jeebana Bhandari, Abish Adhikari, Deepak Yadav, Rijendra Yogal, Rajan Prajapati, Sangam Rayamajhi, Sunil Shrestha, Anjani Kumar Jha","doi":"10.3857/roj.2024.00682","DOIUrl":"10.3857/roj.2024.00682","url":null,"abstract":"Purpose: High-dose-rate (HDR) brachytherapy is a promising treatment modality for organ and function preservation in lip and oral cavity cancers. This study aims to describe the technique and assess clinical outcomes of HDR interstitial brachytherapy in patients diagnosed with lip and buccal mucosa cancer treated in a comprehensive cancer center.Materials and methods: We conducted a retrospective analysis of six lip and four buccal mucosa cancer patients with a median age of 69 years (range, 37 to 90) and equal gender distribution, who underwent exclusive interstitial brachytherapy during the study period from May 2019 to December 2024. All procedures were performed under local anesthesia. Most patients were treated with HDR brachytherapy with a total dose of 40 Gy in 10 fractions over 5 days. Patient characteristics, treatment parameters, cosmetic and functional outcomes, and toxicity were assessed.Results: All patients in this cohort achieved local control and remained in remission at the treatment site throughout the follow-up period. The median duration of follow-up was 29 months (range, 16 to 68). Cosmetic outcomes were rated as good in most of the patients. Any acute and late toxicities experienced were manageable; the most severe acute toxicity observed was grade 3, with late toxicity reaching grade 2.Conclusion: Favorable tumor control, good aesthetic results with manageable toxicity, and the minimally invasive approach highlight interstitial brachytherapy as a compelling single treatment modality for eligible patients with lip and buccal mucosa cancer, particularly in older individuals with significant comorbidities.","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"43 3","pages":"111-119"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12510749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapy omission in low-risk, early-stage breast cancer: a single-center, real-world comparative analysis. 低危、早期乳腺癌的遗漏放疗：一项单中心、真实世界的比较分析。

Radiation oncology journal Pub Date : 2025-09-01 Epub Date: 2025-09-17 DOI: 10.3857/roj.2025.00269

Youngju Song, Sae Byul Lee, Su Ssan Kim, Seung Do Ahn, Jong Won Lee, Jinhong Jung

{"title":"Radiotherapy omission in low-risk, early-stage breast cancer: a single-center, real-world comparative analysis.","authors":"Youngju Song, Sae Byul Lee, Su Ssan Kim, Seung Do Ahn, Jong Won Lee, Jinhong Jung","doi":"10.3857/roj.2025.00269","DOIUrl":"10.3857/roj.2025.00269","url":null,"abstract":"Purpose: This study aimed to compare treatment outcomes between patients who received adjuvant radiotherapy (RT) and those who did not, in a cohort of patients with low-risk, early-stage breast cancer.Materials and methods: Postmenopausal women with pT1N0/Nx, grade 1-2, hormone receptor-positive, human epidermal growth factor 2-negative, and Ki-67 ≤ 20% breast cancer who underwent breast-conserving surgery and adjuvant endocrine therapy between 2010 and 2020 were included. The decision on RT omission was based on physician assessment and patient preference. The primary outcome was cumulative incidence of disease recurrence. Secondary outcomes included locoregional recurrence, overall survival, and breast cancer-specific survival.Results: Of the 742 patients, 707 received adjuvant RT (postoperative radiation therapy [PORT] group) and 35 did not (RT omission group). Baseline characteristics were generally similar; however, the RT omission group was older (median age, 76 years; range, 68 to 85 years) than the PORT group (median age, 62 years; range, 55 to 87 years). After a median follow-up of 60 months in the PORT group and 52 months in the RT omission group, the 5-year cumulative incidence of disease recurrence was 1.28% and 0%, respectively (Gray's test, p = 0.305). Locoregional recurrence occurred in seven patients (1.0%) in the PORT group, whereas no locoregional recurrences were observed in the RT omission group. The results remained consistent after propensity score matching.Conclusion: Low-risk, early-stage breast cancer patients exhibited comparable disease recurrence and survival rates regardless of the RT status. Our study underscores the necessity for further investigation into RT omission in carefully selected patients.","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"43 3","pages":"151-160"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12510750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Feasibility study of dose de-escalation in postoperative intensity-modulated radiation therapy for locally advanced thymoma. 局部晚期胸腺瘤术后调强放疗剂量递减的可行性研究。

Radiation oncology journal Pub Date : 2025-09-01 Epub Date: 2025-09-18 DOI: 10.3857/roj.2025.00255

Youn Ji Hur, Eun Hwa Kim, Hyeok Choi, Sun Ho Min, Jaiwo Lee, Chang Geol Lee

{"title":"Feasibility study of dose de-escalation in postoperative intensity-modulated radiation therapy for locally advanced thymoma.","authors":"Youn Ji Hur, Eun Hwa Kim, Hyeok Choi, Sun Ho Min, Jaiwo Lee, Chang Geol Lee","doi":"10.3857/roj.2025.00255","DOIUrl":"10.3857/roj.2025.00255","url":null,"abstract":"Purpose: This study aimed to investigate retrospectively the feasibility of reducing the standard postoperative radiation therapy (PORT) dose of 45-50 Gy for locally invasive thymoma to shorten treatment duration and minimize side effects, while preserving disease-specific survival (DSS) and progression-free survival (PFS).Materials and methods: Between January 2016 and June 2022, 150 locally advanced thymoma patients underwent surgery followed by intensity-modulated radiation therapy, with a median follow-up of 40.8 months; the standard regimen was 45-50 Gy in 25 fractions (median biological effective dose [BED] 60 Gy), compared to a de-escalation regimen of 30-35 Gy in 10 fractions (median BED 47.25 Gy), with PFS as the primary endpoint, and overall survival (OS), DSS, and toxicity as secondary endpoints.Results: No significant differences were found between standard and de-escalation groups in 3-year PFS (p = 0.406), with both groups achieving 100% 3-year DSS; two deaths in the de-escalation group were due to double primary cancers. All locoregional recurrences occurred outside the radiation field. Factors including age, initial tumor size, myasthenia gravis, and pathological type showed no correlation with PFS or OS. No grade II toxicities occurred in the de-escalation group, whereas the standard group had three cases of grade II toxicity, specifically radiation pneumonitis.Conclusion: Radiation dose de-escalation in locally advanced thymoma patients undergoing PORT showed comparable survival outcomes with reduced toxicity and shorter treatment duration, but requires longer follow-up to confirm efficacy and safety.","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"43 3","pages":"144-150"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12510745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of radiotherapy in the management of breast cancer with skin involvement. 放疗在皮肤受累乳腺癌治疗中的作用。

Radiation oncology journal Pub Date : 2025-06-01 Epub Date: 2025-04-21 DOI: 10.3857/roj.2024.00122

Sun Ho Min, Jee Suk Chang, Yong Bae Kim, Seo Hee Choi, Ik Jae Lee, Jaiwo Lee, Hyeok Choi, Youn Ji Hur, Hwa Kyung Byun

{"title":"Role of radiotherapy in the management of breast cancer with skin involvement.","authors":"Sun Ho Min, Jee Suk Chang, Yong Bae Kim, Seo Hee Choi, Ik Jae Lee, Jaiwo Lee, Hyeok Choi, Youn Ji Hur, Hwa Kyung Byun","doi":"10.3857/roj.2024.00122","DOIUrl":"10.3857/roj.2024.00122","url":null,"abstract":"Purpose: This study aimed to evaluate the effect of radiotherapy (RT) on symptomatic relief and tumor control in patients with breast cancer with skin involvement.Materials and methods: This retrospective study included patients who received palliative RT of the breast or chest wall for breast cancer with skin involvement. Progression-free survival, freedom from local progression (FFLP), and symptomatic response were evaluated. The prescribed dose to tumor was calculated as the biologically effective dose (BED) using α/β of 4. Symptomatic responses were evaluated until 6 months after RT.Results: Of the 43 patients included in this study, 48 Gy in 15 fractions was the most common regimen, and the median BED was 86.4 Gy (range, 24.0 to 120.0). With a median follow-up of 15.1 months (range, 1.6 to 63.5), the median FFLP and progression-free survival were 8.4 and 3.6 months, respectively. The 1-year FFLP rates in patients who received BED >75 Gy and BED ≤75 Gy were 78.3% and 49.7%, respectively (p = 0.046). Within 6 months after RT, 75% of patients showed relief of discharge, 67% showed relief of bleeding, and 37% showed relief of pain. There was no grade 3 or higher skin toxicity or other adverse events.Conclusion: Palliative RT is a safe and effective treatment option for patients with breast cancer with skin involvement, providing symptomatic relief. The administration of BED ≥75 Gy can offer a benefit in achieving durable local control.","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"43 2","pages":"73-78"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dosimetric analysis of different whole brain radiotherapy treatment planning methods: three types of 3-dimensional versus hippocampal avoidant. 不同全脑放射治疗计划方法的剂量学分析：三种类型的三维与海马回避。

Radiation oncology journal Pub Date : 2025-06-01 Epub Date: 2025-04-02 DOI: 10.3857/roj.2023.01039

Jonathan Robert Gabriel, Angela Mariah Locke, Brian William Miller, Jared Rex Robbins

{"title":"Dosimetric analysis of different whole brain radiotherapy treatment planning methods: three types of 3-dimensional versus hippocampal avoidant.","authors":"Jonathan Robert Gabriel, Angela Mariah Locke, Brian William Miller, Jared Rex Robbins","doi":"10.3857/roj.2023.01039","DOIUrl":"10.3857/roj.2023.01039","url":null,"abstract":"Purpose: Our purpose was to compare four whole brain radiotherapy (WBRT) delivery types: opposed lateral (OL) 3-dimensional-conformal radiotherapy (3D-CRT), a novel opposed lateral sparing (OLS) 3D-CRT technique, 3D optimized dynamic conformal arcs (optDCA), and hippocampal-avoidant WBRT (HA-WBRT).Materials and methods: Ten patients previously undergoing HA-WBRT were retrospectively planned using OL, OLS, and optDCA techniques. OLS technique involved multi-leaf collimator (MLC) modifications to protect the lacrimal and parotid glands. OptDCA was inverse-planned 3D-CRT with dynamic conformal arcs. A dosimetric, cost, and resource utilization comparison was performed.Results: Planning target volume coverage to prescription dose between 3D planning techniques was not significantly different between OL and OLS techniques (96.8% vs. 96.6%, p = 0.855), or between OL, OLS, and optDCA (95.0%) techniques (p = 0.079). There was no difference in the heterogeneity index between 3D plans (p = 0.482); all were less heterogeneous than HA-WBRT (p < 0.001). OptDCA was more conformal than OL and OLS, and similar in conformity to HA-WBRT. OLS achieved significant sparing of lacrimal and parotid glands over OL. There were significant step-function reductions in organ at risk (OAR) dose when comparing OL to OLS to optDCA to HA-WBRT plans. HA-WBRT was 57% more expensive than OL and OLS technique. HA-WBRT took approximately six times longer to plan.Conclusion: We showed adequate and equivalent target coverage using OL, OLS, and optDCA techniques. Lacrimal and parotid dosages can be greatly reduced with the implementation of minor MLC adjustments. OptDCA therapy represented further improvement of these modifications, and was comparable to HA-WBRT in terms of OAR dose, while being about two-thirds the cost and more efficient to plan.","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"43 2","pages":"63-72"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0